NCT05884255 2026-04-17
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
Clinical Trials
14 trialsNCT06881992 2026-04-17
Tumor HI
Rezolute
Phase 3 Recruiting
NCT06784752 2026-04-16
NETTER-3
Novartis
Phase 3 Recruiting
NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT07087054 2026-03-10
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3 Recruiting
NCT05918302 2026-03-06
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT06937905 2026-02-11
TARLANEC
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT04706910 2026-02-09
18F-DOPA II - PET Imaging Optimization
University of Alberta
Phase 3 Recruiting
NCT07185672 2025-09-22
PReCedeNT
Tata Memorial Hospital
Phase 3 Recruiting
NCT05387603 2025-09-10
START-NET
Lund University Hospital
Phase 3 Recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT06091748 2025-06-03
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06791005 2025-01-24
A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 3 Recruiting
NCT04847505 2024-07-18
68Ga-DOTA-TATE PET/CT Imaging in NETs
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Phase 3 Recruiting